Spinal Myoclonus Developed during Cervical Epidural Drug Infusion in Postherpetic Neuralgia Patient

Department of Anesthesiology and Pain Medicine, *School of Dentistry, School of Medicine, Kyungpook National University Hospital, Daegu, Korea

Younghoon Jeon, MD*, Sung Uk Baek, MD, and Jin Seok Yeo, MD

Postherpetic neuralgia is the most frequent complication of herpes zoster. Treatment of this neuropathic pain syndrome is difficult and often disappointing. Although postherpetic neuralgia is generally a self-limited condition, it can last indefinitely. Continuous epidural blockade for patients with acute zoster can shorten the duration of treatment. However, continuous epidural block has some complications such as infection, dural puncture, and total spinal and nerve damages. We report a case of myoclonus during continuous epidural block with ropivacaine, morphine, and ketamine in an acute zoster patient. (Korean J Pain 2011; 24: 169-171)

Key Words:
analgesia, complication, epidural, myoclonus.

Postherpetic neuralgia is the most frequent complication of herpes zoster. Treatment of this neuropathic pain syndrome is difficult and often disappointing. Continuous epidural blockade for patients with acute zoster can shorten the duration of the treatment. Continuous epidural blockade has some complications such as infection, vascular injection, dural puncture, total spinal anesthesia, and nerve damage. Spinal myoclonus after neuraxial blockade is very rare complication. We report a case of bilateral myoclonus during continuous cervical epidural block with ropivacaine, morphine, and ketamine and review the related literature.

CASE REPORT

A 61-year-old female came to our pain clinic and presented with erythematous vesicles and pain on the right side of her arm for 2 weeks. She had no significant past or family medical history. Initial physical examination of the patient showed grouped vesicles and crusts on an erythematous skin lesion, scattered along the right C5 dermatome. The intensity of pain using the visual analogue scale (VAS) from 0 to 10 (0 = no pain, 10 = worst pain imaginable) was 8. She complained of burning and lancinating pain, hyperesthesia, and sleep disturbance due to night pain on the affected dermatome.
She had been treated with famciclovir (FAMVIR®, Novartis, USA) 250 mg 3 times a day and prednisolone (Lyrica®, Pfizer Korea, Korea) 150 mg twice a day and a tramadol/acetaminophen tablet (Ultracet®, Yansen Korea, Korea) 3 times a day orally for 7 days. Complete blood count, urine analysis, blood chemistry, electrocardiogram, and chest and spine radiographs were all within normal limits. In medical history, she was free of neurological disorders such as cerebral infarction, epilepsy, or Parkinson’s disease.

After discussing with the patient, continuous epidural analgesia was selected for treatment of the herpes-zoster–induced pain. In the outpatient department of our pain clinic, an 18–G epidural catheter was inserted 3 cm cephalad through a 17–G Tuohy needle to the C6–7 interspace. The epidural space was detected by the hanging drop technique. Catheterization of the epidural space was done, and no blood or cerebrospinal fluid was aspirated through the catheter. The patient did not complain of any paresthesia during the procedure. An epidural injection of 5 mL of 0.2% plain ropivacaine produced bilateral sensory block of the C5–7 dermatomes determined by the pinprick method. Continuous epidural infusion was started with 0.2% ropivacaine 4 mL/h and morphine sulfate 0.2 mg/h with a portable disposable pump.

After 7 days, she visited our outpatient pain clinic and her VAS score had decreased to 5, but she still complained of burning sensations and lancinating pain. Therefore, we administered 0.2% ropivacaine 4 mL/h and morphine sulfate 0.4 mg/h, and ketamine 1 mg/hepidurally.

On the third day after infusion of this analgesic regimen, she showed bilateral involuntary movement of both hands. Brief, involuntary twitching of the muscle in both hands persisted for about 2–3 minutes intermittently, and it occurred several times an hour. An MRI on the head and cervical spine was done and a neurologist assessed the patient’s neurological deficits. However, there were no neurological deficits, no abnormal findings on the MRI, and no electrolyte imbalances in the blood sample. Therefore, we diagnosed spinal myoclonus. Therefore, we stopped epidural infusion and removed the epidural catheter. Thirty–six hours after stopping the infusion, her involuntary movement ceased. We decided to maintain her previous oral medication to control for pain and discharged her without any complications. At that time, her VAS score was 5.

**DISCUSSION**

Myoclonus is comprised of sudden, involuntary contractions of a group of muscles, a single muscle, or part of a muscle. Spinal, focal, or segmental myoclonus has specific features that distinguish it from other forms of more generalized myoclonus. It is often restricted to one somatic region due to the pathology at the involved level of the spinal cord. The appearance of myoclonus may take several months or years. The possible causes are tumor, infection, trauma, and degenerative processes [2]. The pathophysiology of spinal myoclonus includes abnormal loss of inhibition from suprasegmental descending pathways, loss of inhibition from local dorsal horn interneurons, hyperactivity of contiguous anterior horn neurons, and aberrant local axon re–excitations [3].

Neuraxial high dose opioid therapy may cause spinal myoclonus [4,5]. Kloke et al. [4] reported 10 cases of myoclonus among spinal opioid therapy patients. In addition, spinal cord or nerve lesions are risk factors of myoclonus. Medullar spinalis lesions are associated with increased risk of myoclonus because of combination of spinal-cord/nerve lesions are risk factors of myoclonus. In our case, the patient did not receive a high dose of neuraxial opioid. Additionally, she did not have spinal cord lesions. Therefore, this case of spinal myoclonus is unlikely opioid induced.

Local anesthetic neurotoxicity may cause spinal myoclonus [6]. It was postulated that the inhibitory effects of the local anesthetic might lead to heightened irritability of the α–motor neurons, leading to myoclonus [7]. However, ropivacaine used in this case is known to be the least neurotoxic local anesthetics [8].

Zoster myelitis can cause spinal myoclonus [9], but it is not a cause of myoclonus in this case since myoclonus appeared and disappeared as the ketamine infusion was started and stopped, respectively, and there were no myelitis lesions in the MRI.

Indwelling spinal or epidural catheters may cause myoclonus by irritating the spinal cord or nerve roots [10]. This can be treated immediately by withdrawing the offending catheter. In this case, myoclonus continued for 36 hours after catheter removal. Therefore, we excluded catheter–induced myoclonus.
Ketamine may induce seizure activity [11,12]. Ketamine may cause seizure activity either in the form of cortical electroencephalograph (EEG) or clinical seizure activity in epileptics in whom the drug activates subcortical activity [11,12]. Additionally, nutritional and environmental factors (smoking, alcohol, diet) and drug interactions may influence the metabolic and pharmacokinetic patterns of ketamine contributing to proconvulsant activity. Potter et al., suggested that myoclonus, as a side effect of treatment with morphine, is more likely to occur in patients taking antidepressants, antipsychotic drugs, antiemetics, or non-steroidal inflammatory drugs for additional analgesia [13]. In this case, we added ketamine for additional analgesia just 2 days before myoclonus developed and myoclonus resolved 36 hours after catheter removal. Therefore, we postulate that the ketamine may be responsible for the spinal myoclonus.

The treatment of spinal myoclonus includes the detection and abolition of the etiology and symptomatic treatment with benzodiazepines or anticonvulsants [3]. Discontinuation of drugs suspected of causing myoclonus and treatment of metabolic derangements may resolve some cases of myoclonus. When pharmacological treatment is indicated, anticonvulsants are the main line of treatment. Treatment of myoclonus focuses on medications that may help reduce symptoms. The various drugs used include anticonvulsants such as sodium valproate, clonazepam, and benzodiazepines, which include diazepam and midazolam [14].

In conclusion, spinal myoclonus following epidural analgesia is rare, but the clinician should watch out for this complication, especially in patients using morphine and an adjuvant drug.

REFERENCES

1. Sim WS, Choi JH, Han KR, Kim YC. Treatment of herpes zoster and postherpetic neuralgia. Korean J Pain 2008; 21: 93–105.
2. Hoehn MM, Cherington M. Spinal myoclonus. Neurology 1977; 27: 942–6.
3. Caviness JN, Brown P. Myoclonus: current concepts and recent advances. Lancet Neurol 2004; 3: 598–607.
4. Kloke M, Bingel U, Seeber S. Complications of spinal opioid therapy: myoclonus, spinal muscle tone and spinal jerking. Support Care Cancer 1994; 2: 249–52.
5. Cartwright PD, Hesse C, Jackson AO. Myoclonic spasms following intrathecal diamorphine. J Pain Symptom Manage 1993; 8: 492–5.
6. Fox EJ, Villanueva R, Schulte HS. Myoclonus following spinal anesthesia. Neurology 1979; 29: 379–80.
7. Menezes FV, Venkat N. Spinal myoclonus following combined spinal–epidural anaesthesia for Caesarean section. Anaesthesia 2006; 61: 597–600.
8. Yamashita A, Matsumoto M, Matsumoto S, Ishi M, Kawai K, Sakabe T. A comparison of the neurotoxic effects on the spinal cord of tetracaine, lidocaine, bupivacaine, and ropivacaine administered intrathecally in rabbits. Anesth Analg 2003; 97: 512–9.
9. Jankovic J, Pardo R, Segmental myoclonus. Clinical and pharmacologic study. Arch Neurol 1986; 43: 1025–31.
10. Ford B, Pullman SL, Khondji A, Goodman R. Spinal myoclonus induced by an intrathecal catheter. Mov Disord 1997; 12: 1042–5.
11. Mori K, Kawamata M, Mitani H, Yamazaki Y, Fujita M. A neurophysiologic study of ketamine anesthesia in the cat. Anesthesiology 1971; 35: 373–83.
12. Hirshman CA, Krieger W, Littlejohn G, Lee R, Julien R. Ketamine–aminophylline–induced decrease in seizure threshold. Anesthesiology 1982; 56: 464–7.
13. Potter JM, Reid DB, Shaw RJ, Hackett P, Hickman PE. Myoclonus associated with treatment with high doses of morphine: the role of supplemental drugs. BMJ 1989; 299: 150–3.
14. Andrade DM, Hamani C, Minassian BA. Treatment options for epileptic myoclonus and epilepsy syndromes associated with myoclonus. Expert Opin Pharmacother 2009; 10: 1549–60.